Novo Nordisk Statistics
Total Valuation
Novo Nordisk has a market cap or net worth of $391.83 billion. The enterprise value is $402.54 billion.
Important Dates
The last earnings date was Wednesday, February 5, 2025, before market open.
| Earnings Date | Feb 5, 2025 |
| Ex-Dividend Date | Mar 31, 2025 |
Share Statistics
Novo Nordisk has 4.44 billion shares outstanding. The number of shares has decreased by -0.71% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 4.44B |
| Shares Change (YoY) | -0.71% |
| Shares Change (QoQ) | -0.11% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 3.18B |
Valuation Ratios
The trailing PE ratio is 27.95 and the forward PE ratio is 22.75.
| PE Ratio | 27.95 |
| Forward PE | 22.75 |
| PS Ratio | 9.72 |
| Forward PS | 1.14 |
| PB Ratio | 19.67 |
| P/TBV Ratio | 87.13 |
| P/FCF Ratio | 37.85 |
| P/OCF Ratio | 23.33 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 19.77, with an EV/FCF ratio of 38.89.
| EV / Earnings | 28.71 |
| EV / Sales | 9.99 |
| EV / EBITDA | 19.77 |
| EV / EBIT | 20.73 |
| EV / FCF | 38.89 |
Financial Position
The company has a current ratio of 0.74, with a Debt / Equity ratio of 0.72.
| Current Ratio | 0.74 |
| Quick Ratio | 0.52 |
| Debt / Equity | 0.72 |
| Debt / EBITDA | 0.69 |
| Debt / FCF | 1.38 |
| Interest Coverage | 85.29 |
Financial Efficiency
Return on equity (ROE) is 80.78% and return on invested capital (ROIC) is 46.03%.
| Return on Equity (ROE) | 80.78% |
| Return on Assets (ROA) | 22.41% |
| Return on Invested Capital (ROIC) | 46.03% |
| Return on Capital Employed (ROCE) | 56.34% |
| Revenue Per Employee | $521,201 |
| Profits Per Employee | $181,248 |
| Employee Count | 77,349 |
| Asset Turnover | 0.74 |
| Inventory Turnover | 1.20 |
Taxes
In the past 12 months, Novo Nordisk has paid $3.64 billion in taxes.
| Income Tax | 3.64B |
| Effective Tax Rate | 20.60% |
Stock Price Statistics
The stock price has decreased by -27.48% in the last 52 weeks. The beta is 0.19, so Novo Nordisk's price volatility has been lower than the market average.
| Beta (5Y) | 0.19 |
| 52-Week Price Change | -27.48% |
| 50-Day Moving Average | 88.64 |
| 200-Day Moving Average | 117.58 |
| Relative Strength Index (RSI) | 56.29 |
| Average Volume (20 Days) | 9,595,927 |
Short Selling Information
| Short Interest | 13.57M |
| Short Previous Month | 8.30M |
| Short % of Shares Out | 0.43% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 1.47 |
Income Statement
In the last 12 months, Novo Nordisk had revenue of $40.31 billion and earned $14.02 billion in profits. Earnings per share was $3.14.
| Revenue | 40.31B |
| Gross Profit | 34.27B |
| Operating Income | 19.42B |
| Pretax Income | 16.54B |
| Net Income | 14.02B |
| EBITDA | 20.36B |
| EBIT | 19.42B |
| Earnings Per Share (EPS) | $3.14 |
Full Income StatementBalance Sheet
The company has $3.65 billion in cash and $14.27 billion in debt, giving a net cash position of -$10.62 billion or -$2.39 per share.
| Cash & Cash Equivalents | 3.65B |
| Total Debt | 14.27B |
| Net Cash | -10.62B |
| Net Cash Per Share | -$2.39 |
| Equity (Book Value) | 19.92B |
| Book Value Per Share | 4.49 |
| Working Capital | -7.86B |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $16.79 billion and capital expenditures -$6.55 billion, giving a free cash flow of $10.35 billion.
| Operating Cash Flow | 16.79B |
| Capital Expenditures | -6.55B |
| Free Cash Flow | 10.35B |
| FCF Per Share | $2.33 |
Full Cash Flow StatementMargins
Gross margin is 85.00%, with operating and profit margins of 48.17% and 34.78%.
| Gross Margin | 85.00% |
| Operating Margin | 48.17% |
| Pretax Margin | 43.80% |
| Profit Margin | 34.78% |
| EBITDA Margin | 50.51% |
| EBIT Margin | 48.17% |
| FCF Margin | 25.68% |
Dividends & Yields
This stock pays an annual dividend of $1.30, which amounts to a dividend yield of 1.48%.
| Dividend Per Share | $1.30 |
| Dividend Yield | 1.48% |
| Dividend Growth (YoY) | -5.23% |
| Years of Dividend Growth | 3 |
| Payout Ratio | 41.38% |
| Buyback Yield | 0.71% |
| Shareholder Yield | 2.18% |
| Earnings Yield | 3.58% |
| FCF Yield | 2.64% |
Dividend DetailsAnalyst Forecast
The average price target for Novo Nordisk is $141.67, which is 60.84% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $141.67 |
| Price Target Difference | 60.84% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | 12.90% |
| EPS Growth Forecast (5Y) | 15.61% |
Stock ForecastsStock Splits
The last stock split was on September 20, 2023. It was a forward split with a ratio of 2:1.
| Last Split Date | Sep 20, 2023 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
Novo Nordisk has an Altman Z-Score of 8.94 and a Piotroski F-Score of 5.
| Altman Z-Score | 8.94 |
| Piotroski F-Score | 5 |